Theravance Biopharma (TBPH) Cash from Investing Activities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Cash from Investing Activities data on file, last reported at $52.6 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $52.6 million, up 71.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$83.3 million (down 421.86% YoY), and the FY2025 annual result was -$105.3 million, down 957.08% from the prior year.
• Cash from Investing Activities climbed to $52.6 million in Q1 2026 per TBPH's latest filing, from $588000.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $1.1 billion in Q4 2022 and troughed at -$100.2 million in Q3 2025.
• A 5-year average of $63.6 million and a median of $588000.0 in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities soared 10379.44% in 2022, then plunged 82752.38% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $1.1 billion in 2022, then slumped by 100.06% to -$677000.0 in 2023, then surged by 2416.99% to $15.7 million in 2024, then sank by 96.25% to $588000.0 in 2025, then soared by 8844.39% to $52.6 million in 2026.
• Business Quant data shows TBPH's Cash from Investing Activities at $52.6 million in Q1 2026, $588000.0 in Q4 2025, and -$100.2 million in Q3 2025.